The biotech funding environment has undergone significant changes in the last two years. Record-high levels of investment fell drastically, despite the availability of capital, creating more competitive markets that are spurring new approaches and perspectives within emerging biotech even as key funding players reshape the field. This incredibly dynamic sector is busy transforming uncertainty to opportunity.
Market snapshot
The biotechnology sector’s funding environment has undergone significant changes in the last few years, demanding creative solutions in response. The record-highs of the bull market that gained critical mass through the late 2010s and early 2020s has stopped short. Interest rates are up and the once-hot biotech IPO market has crashed, alongside its related model, the SPAC, effectively reducing capital and returns expected by Series A investors, and market instability has shaken investors. The quick-flowing funds that were in the market in 2021 have been bottled up by 2022, resulting in fundraises that have – after two record-setting years – dipped 24%.
Tide changes
Venture capital funding, typically the primary source of investment for biotech, especially early-stage, is at its lowest level since 2019. VCs have battened the hatches as they triage their portfolios, with their portfolio companies making survival cuts to pipelines and staff. With VCs shifting focus from growing to surviving, more of their capital is reserved for their existing portfolios – meaning less is available for investment.
The recent turbulence in the banking sector stoked anxieties in the market, but rapid moves to stabilise the situation and secure the deposits held on behalf of thousands of biotech companies seem to have alleviated the tension.
Large pharma uses the biotech market to augment their pipelines, but they have been sitting on substantial reserves of capital with Big Pharma stockpiling upwards of $330bni. M&A activity has also been sparse, although some large deal announcements have been made recently, including Merck & Co.’s acquisition of Prometheus Biosciences for a total value of $10.8bn, and GSK’s acquisition of BELLUS Health Inc, valuing it at $2.0bn. More M&A is expected in the face of the looming patent cliff for large pharma, because biotech is still the industry’s innovation machine.
More mouths to feed
There are more biotech companies now than ever before. Consequently, there is a large tranche of early-stage biotech in need of venture funding, precisely at a time when access to that funding has stifled. The funding market has become incredibly competitive, even in Series A which has been the most stable, and traditionally last to be impacted by macroeconomic pressures, compared to late stage and crossover investmentsii. Bay Bridge Bio estimate there to be an $8bn shortfall of follow-on capital for Series A companies compared to a year agoiii.
This lack of growth capital for many biotech companies means they must be very cautious in their spending, again resulting in pipeline culls and rounds of layoffs. In total, more than 100 biotech companies laid off employees in 2022, with more anticipated through 2023iv. Reprioritising pipelines and optimising development strategies will help biotech stretch their cash to advance their programs in the absence of additional capital investment.
Emerging funding trends
Although existing funds have tightened the purse strings, new funds are forging ahead, showing positive vital signs for the sector in Europe. Some very large EU-based funds have recently closed, including Forbion, who closed more than $1.5bn across two separate funds, and Gilde Healthcare who raised $657m for their Venture & Growth VI fund. Other EU funds closed recently include Lux Capital, Wellington, Canaan, Cure Ventures, EQT Life Sciences and SR One, so there is plenty of capital available to support the right science.
These newly minted funds are not just a sign of good health, they are a vital source of infusion – in early 2022, emerging VCs outpaced established VCs in the number of new Series A investmentsv. With smaller or non-existent portfolios, emerging VCs have the freedom to invest more of their funds as opposed to established VCs with fuller portfolios to keep afloat.
Additional sources of private capital are starting to come in from some large private equity firms as they acquire VCs to diversify their own portfolios (e.g., Blackstone’s acquisition of Clarus Ventures in 2018, and more recently EQT Group Stockholm’s acquisition of Life Sciences Partners of the Netherlands). As PEs seek new and exciting channels for investment, this trend is likely to continue.
Biotech forges on
The European market continues to exhibit strong R&D activity. Although American markets have more favourable valuations, Europe has historically been and continues to be a significant accelerator for biotech and life science progress.
Biotech have had to adjust their approaches to securing funding amid a much more competitive market for the funds that are distributed. The IPO route that offered an efficient profitability option with good historical returns, has been essentially closed for the past year due to the downturn in global stock markets (particularly NASDAQ), and private investment has become highly selective, requiring clearer demonstrations of value and utility. The other funding options open to biotech are being acquired by larger pharma or striking partnership deals. Large pharma has long used biotech to augment their development pipelines, but they prefer high-quality, de-risked assets (Prometheus Biosciences’ lead asset was Phase 3 ready when it was acquired for $11bn).
We are seeing more biotech perform early economic evaluations at proof-of-concept and pre-regulatory approval stages, but more strategic planning and positioning will be key for navigating the new funding environment and landing the critical Series A investments.
Uncertainty to opportunity
Biotech’s contribution to the global R&D pipeline has been growing in the last decade, with 2018 seeing emerging companies account for over 70% of the entire global industry pipeline, according to BIO Industry Analysis, May 2018. Now, with larger early fundraises in the past two years and the continued drop-off in subsequent series raises, there are fewer viable options for early exit strategies and liquidity events, and more biotech are taking their development further themselves before partnering or selling.
The current funding climate requires biotech to think harder about their approach than they had to in the bull market. Now, they are outsourcing more strategically and designing more cost-effective trials to stretch their cash runways and carry them further along the development continuum. For our part, we see more biotech seeking consultative partnerships, trending away from the smaller or regional service providers to leverage the breadth of expertise offered by global CROs. Biotech are leveraging early engagement opportunities with full-service partners to optimise the impact of external expertise across the development program, and to maximise their probability of success.
Connect with us to see how ICON’s team of 8,000 dedicated biotech specialists can provide comprehensive, tailored solutions across areas such as asset due diligence, clinical development planning, Target Product Profile optimisation and regulatory strategy.
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel